- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03808779
A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.
A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The incidence of thyroid carcinoma, especially the papillary thyroid microcarcinoma (PTMC), has increasingly rapidly, due to the development of technologies of diagnosis, during the past 20 years. PTMC defined by the World Health Organization (WTO) as the largest dimension less than 1 cm. Previous autopsy study demonstrated that the lesions are normal in many people and accompany them latently until they die because of another reasons. The long-term outcome of PTMC is good and, as expected, more than 90% PTMC aren't progress for many years.
Ultrasound-guided Radiofrequency Ablation (RFA) treatment was introduced to clinical practice few years ago. According to the 2015 American Thyroid Association (ATA) guideline, the treatment of radiofrequency and laser ablation are mentioned to be used in recurrent thyroid cancer. But clinical practice shows that the RFA treatment for low risk PTMC braces well effect,low financial budget,high safety and even rare postoperative complication.
Although the cohort study was performed before, the real answer concerning about whether RFA is a rational choice for treating PTMC lacks more powerful evidences. The investigator considers to perform a randomized, controlled and multicenter study as a high-quality evidence and demonstrated the effect of PRF in low risk PTMC treatment.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jifan Chen, collegue
- Phone Number: +8613605771565
- Email: chenjifan0619@163.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 022
- Recruiting
- General Surgery Department, Tianjin Medical University General Hospital
-
Contact:
- Jie Zhang, director
- Phone Number: +8615822798742
- Email: wzq_bf@163.com
-
Contact:
- Ruoyu Jiang, collegue
- Phone Number: +8618622632394
- Email: jiangruoyu000@aliyun.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 0571
- Recruiting
- Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University
-
Contact:
- Jifan Chen, collegue
- Phone Number: +8613605771565
- Email: chenjifan0619@163.com
-
-
-
-
-
Kharkiv, Ukraine, 61024
- Not yet recruiting
- Interventional Oncology Centre, State Institution "Grigoriev Intstitute for Medical Radiology NAMS of Ukraine"
-
Contact:
- Sviatoslav Balaka
- Phone Number: +380509356958
- Email: balaka.svjat@gmail.com
-
Contact:
- Hennadii Hrechikhin
- Phone Number: +380509188586
- Email: interv.oncology@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly diagnosis of PTMC (largest dimension<10mm)
- Age >=18 years old
- Bethesda Category V or VI
- Single nodule without thyroid capsule contact
- Nodule has more than 3mm distance far from recurrent laryngeal nerve, carotid artery and trachea.
- No clinical evidences show there is local or distant metastasis.
- Without chemotherapy, radiotherapy and other related therapies.
- Patients and their family member totally understand and sign the informed consent.
Exclusion Criteria:
- Multifocal PTMC
- Combined with other types of thyroid cancer or hyperthyroidism.
- Contralateral vocal cord paralysis
- With local or distant metastasis
- Pregnant woman
- With radiation exposure history
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Radiofrequency Ablation
Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
|
Patients were supine with the neck exposure completely during the procedure.
Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule.
If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury.
RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds.
The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence.
The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.
Other Names:
|
Active Comparator: Conventional Surgery
Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
|
Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon.
Patients are routinely disinfected and spread the drapes after general anesthesia.
Neck skin, fat and placenta muscle are incised and separated successively.
The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated.
Then both sides thyroid lobes are exposed.
Cut off the isthmus, ligature the thyroid artery, cut off the upper pole.
Ligature and cut off the ipsilateral thyroid vein.
Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrent-free Survival Rate
Time Frame: 5 years
|
record detecting recurrence of PTMC post-surgery or post-FRA
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Diameter of Lesion
Time Frame: 5 years
|
record diameter reduce rate after RFA procedure
|
5 years
|
The Volume of Lesion
Time Frame: 5 years
|
record volume reduce rate after RFA procedure
|
5 years
|
Postoperative Complications
Time Frame: up to 12 months
|
record relevant complications after surgery or RFA
|
up to 12 months
|
Serum Concentration of Serological Examination of Thyroid Function
Time Frame: up to 12 months
|
record the serum concentration of TSH/T3/FT3/T4/FT4/TPOAb/TgAb/TRAb.
|
up to 12 months
|
Medical Cost
Time Frame: up to 12 months
|
record hospital expenditure
|
up to 12 months
|
Hospital Duration
Time Frame: through study completion, an average of 7 days
|
record hospital stay time
|
through study completion, an average of 7 days
|
Patient Satisfaction: questionnaire
Time Frame: 5 years
|
measured by satisfaction questionnaire designed by investigator group: items: 1.Are you satisfied with surgery? 2.Are you satisfied with the RFA procedure? scale range from 1 to 10; by the increasing of scale, the outcome is defined as good. |
5 years
|
Anxiety index measured by psychological questionnaire
Time Frame: up to 5 years
|
scale range from 1 to 4 For the question 5,9,13,17,18, the outcome is define as good by the increasing of scale. For the others, the outcome is defined as bad by the increasting of scale.(scale 1=No or very few, scale2=sometimes, scale3=often, scale4=always) |
up to 5 years
|
Overall Survival in Patients with PTMC
Time Frame: 5 years
|
record 5 year overall survival
|
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Pintong Huang, director, Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-004-A012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Papillary Thyroid Microcarcinoma
-
European Institute of OncologyRecruiting
-
National Cancer Institute, NaplesRecruitingPapillary Microcarcinoma of the ThyroidItaly
-
Mayo ClinicActive, not recruitingPapillary Thyroid Cancer | Papillary Thyroid MicrocarcinomaUnited States
-
University Health Network, TorontoUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); CHU de Quebec-Universite Laval and other collaboratorsRecruitingPapillary Thyroid Carcinoma | Papillary Thyroid Cancer | Papillary Microcarcinoma of the ThyroidCanada
-
Yonsei UniversityCompletedPapillary Thyroid MicrocarcinomaKorea, Republic of
-
Seoul National University HospitalRecruitingThyroid Cancer | Papillary Thyroid MicrocarcinomaKorea, Republic of
-
Korean Association of Endocrine SurgeonsCompletedPapillary Thyroid MicrocarcinomaKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterCompletedThyroid Cancer | Papillary MicrocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingThyroid | Thyroid Cancer | Papillary Thyroid MicrocarcinomaUnited States
-
Seoul National University HospitalActive, not recruitingThyroid Cancer | Papillary Thyroid MicrocarcinomaKorea, Republic of
Clinical Trials on Radiofrequency Ablation
-
Xijing HospitalUnknown
-
Assistance Publique - Hôpitaux de ParisTerminatedHepatocellular CancerFrance
-
Oxford University Hospitals NHS TrustRoyal Bournemouth and Christchurch Hospitals NHS Foundation TrustCompleted
-
Mansoura UniversityUnknownChronic Knee OsteoarthritisEgypt
-
Allevio Pain Management ClinicRecruitingShoulder Pain Chronic | Faceto-genic Neck Pain | Faceto-genic HeadacheCanada
-
Southwest Hospital, ChinaCompleted
-
University of CalgaryRecruitingOsteoarthritis, KneeCanada
-
Assistance Publique - Hôpitaux de ParisCompletedHepatocellular CarcinomasFrance
-
Hangzhou Broncus Medical Co., Ltd.Shanghai Chest HospitalRecruitingStage IA Lung CancerChina
-
Aalborg University HospitalOdense University Hospital; St. Antonius HospitalTerminatedParoxysmal Atrial Fibrillation.Netherlands, Denmark